Literature DB >> 7496871

Modulation of cytokine release from human monocytes by drugs used in the therapy of inflammatory bowel diseases.

K F Bruin1, D W Hommes, J Jansen, G N Tytgat, J Wouter ten Cate, S J van Deventer.   

Abstract

BACKGROUND: Cytokines produced in the gut mucosa play an important role in the pathogenesis of inflammatory bowel diseases (IBD). To determine whether drugs used in the treatment of these diseases modulate cytokine synthesis, we investigated their effects on endotoxin-induced tumour necrosis factor (TNF)-alpha, interleukin (IL)-1 beta and IL-6 release by elutriation-purified human monocytes in vitro.
METHODS: Drugs tested were dexamethasone, 5-aminosalicylic acid, sulphapyridine and zileuton (a 5-lipoxygenase inhibitor). Monocytes were isolated and stimulated with endotoxin, and TNF, IL-1 and IL-6 levels were determined using an enzyme-linked immunosorbent assay.
RESULTS: Monocyte stimulation with endotoxin resulted in an average TNF release of 2464 +/- 64 pg/10(6) cells, IL-1 release of 616 +/- 47 pg/10(6) cells and IL-6 release of 2259 +/- 148 pg/10(6) cells. Addition of dexamethasone resulted in a reduction of TNF, IL-1 and IL-6 release to below background levels. Sulphapyridine significantly reduced TNF and induced IL-1 release in a dose-dependent fashion, but had no significant effect on IL-6 release. 5-Aminosalicylic acid did not modulate IL-6 synthesis, but significantly reduced IL-1 and enhanced TNF synthesis. Zileuton reduced TNF and IL-6 release, but enhanced IL-1 release.
CONCLUSION: We conclude that these anti-inflammatory drugs are able to modulate cytokine release by human monocytes. Further studies are needed to determine whether these effects are related to their therapeutic efficacy in IBD.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7496871

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  5 in total

Review 1.  Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

2.  Inflammation in the pathogenesis of lyme neuroborreliosis.

Authors:  Geeta Ramesh; Peter J Didier; John D England; Lenay Santana-Gould; Lara A Doyle-Meyers; Dale S Martin; Mary B Jacobs; Mario T Philipp
Journal:  Am J Pathol       Date:  2015-04-16       Impact factor: 4.307

3.  A possible role for inflammation in mediating apoptosis of oligodendrocytes as induced by the Lyme disease spirochete Borrelia burgdorferi.

Authors:  Geeta Ramesh; Shemi Benge; Bapi Pahar; Mario T Philipp
Journal:  J Neuroinflammation       Date:  2012-04-23       Impact factor: 8.322

4.  Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn's disease.

Authors:  Glen A Doherty; Mark A Peppercorn
Journal:  Clin Exp Gastroenterol       Date:  2009-12-08

Review 5.  Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.

Authors:  A Prakash; A Markham
Journal:  Drugs       Date:  1999-03       Impact factor: 11.431

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.